Long-acting NK-1 receptor antagonist rolapitant demonstrates significant efficacy in managing CINV in patients receiving HEC or MEC for cancer.
Many patients can still experience UA-RINV despite prophylactic therapy; therefore, researchers explored the effectiveness and safety of dual prophylactic therapy with an NK1 receptor antagonist and a 5-HT3 receptor antagonist.
The Multinational Association of Supportive Care in Cancer (MASCC) and the European Society for Medical Oncology (ESMO) have updated their recommendations for the prevention of nausea and vomiting following multiple-day chemotherapy.
Adding rolapitant to a 5-HT3 receptor antagonist and dexamethasone significantly improved the prevention of CINV in patients with GI and CRC cancers receiving highly or moderately emetogenic chemotherapy.
Adding rolapitant to a 5-HT3 receptor antagonist and dexamethasone improved quality of life.
Including an antiemetic in the preprocedure medications for patients with liver cancer undergoing drug eluting bead chemoembolization (DEB TACE) can shorten hospital stays and reduce the chance for readmission due to complications.
[Cancer Management and Research] This review focuses on dronabinol and its role in the treatment of chemotherapy-induced nausea and vomiting (CINV).
Loss of appetite and not eating are difficult aspects of cancer for patients' loved ones to understand. Continued and diligent nurse education can help both patients and families cope with this disturbing effect.
Personalized Antinausea Regimens More Effective in Cancer Patients Receiving Emetogenic ChemotherapyNovember 23, 2015
A personalized approach to treating nausea and vomiting, the most expected side effects of chemotherapy, is far more effective than the existing one-size-fits-all guidelines.
Ramosetron plus dexamethasone and aprepitant is as effective and tolerable as ondansetron.
Clinically relevant psychotropic side effects plus ineffectiveness halted study of cannabis use to prevent postoperative nausea.
Rolapitant demonstrates superiority over active control for the prevention of chemotherapy-induced nausea and vomiting.
The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomitingJuly 17, 2015
[Cancer Management and Research] This research examines the incidence of chemotherapy-induced nausea/vomiting (CINV) and treatment delay among patients receiving palonosetron versus other 5-hydroxytryptamine receptor antagonist (5-HT3 RA) antiemetics.
There is a perpetual gap between healthcare professionals and patient perceptions of incidence and impact on patients' daily life of CINV/RINV.
Granisetron transdermal system (GTS) may be appropriate for prevention of chemotherapy-induced nausea and vomiting (CINV) in lung cancer.
Is a comparison guide for common medications used for side-effect management, such as constipation, nausea, anxiety, etc. that includes a cost comparison available?
Akynzeo approved for the treatment chemotherapy-induced nausea and vomiting (CINV) in patients with cancer.
For patients receiving cisplatin-based chemotherapy, rolapitant can reduce nausea-related side effects.
Could a medication indicated for nausea and vomiting in pregnancy resolve the same symptoms in patients undergoing chemotherapy?
A ginger extract, 6-gingerol, improves chemotherapy-induced nausea and vomiting (CINV), according to findings from a phase 2 randomized trial presented at the 2014 Annual ASCO Meeting.
Patients who express pretreatment concern about treatment symptoms such as nausea and memory problems tend to suffer higher symptom burdens during and after anticancer treatment, suggests research.
What can nurses do to advocate for the use of medications such as lorezepam (Ativan) for anticipatory nausea when the physician is reluctant to prescribe antianxiety or sleep medications?
The final data from a phase II study confirmed the high degree of activity of quizartinib in persons with acute myeloid leukemia.
Ibrutinib, which targets the Bruton's tyrosine kinase to combat chronic lymphocytic leukemia, showed promising results in two phase II studies.
The 32-mg, single IV dose of the anti-nausea drug Zofran (ondansetron) will no longer be sold due to the potential for serious cardiac risks.
This fact sheet contains tips for patients dealing with nausea and loss of appetite resulting from cancer treatment.
Lidiando con las Nauseas y Vomitos Inducidos por la Quimioterapia (Coping with Chemotherapy-Induced Nausea and Vomiting)September 18, 2012
This fact sheet is written in Spanish to help patients cope with nausea and vomiting associated with chemotherapy.
The FDA has approved tbo-filgrastim to treat certain cancer patients undergoing chemotherapy who have severe neutropenia.
Consuming 8 ounces of grapefruit juice increases sirolimus levels by 350%, allowing persons with cancer to take less toxic doses of the drug.
Adding dexamethasone to prochlorperazine on days two and three reduces delayed nausea after chemotherapy.
- Clinical Trials May Benefit Oncology Patients
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Immune Thrombocytopenia (Fact Sheet)
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Rates of Infection with Clostridium Difficile Increase Over Time in Patients With Cancer
- Metabolism of Next-Generation Prostate Cancer Drugs Share Similarities
- Nivolumab Improves Clinical Outcomes in Patients With Relapsed-Refractory Hodgkin Lymphoma After ASCT, Brentuximab Vedotin
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|